Description
The
free PSA [125I] IRMA system provides a direct quantitative in
vitro determination of human free prostate specific antigen (fPSA) in
human serum. Free PSA can be assayed in the range of 0-50 ng/ml using
100 µl serum samples. Each kit contains materials sufficient for 100
assay tubes permitting the construction of one standard curve and the
assay of 43 (42) unknowns in duplicate.
Introduction
Prostate specific antigen (PSA) is a tissue-specific serine protease
similar to the chymotrypsin- like glandular kallikreins. The active
enzyme is a single chain glycoprotein of 237 amino acids (approximately
30 kDa). PSA is mainly responsible for gel dissolution in freshly
ejaculated semen by proteolysis of the major gel forming proteins. The
major part (70-90%) of prostate specific antigen in serum is complexed
to alpha1-antichymotrypsin (ACT). Total PSA (free +
ACT-complex) is increased in both benign prostate hyperplasia and
malignant prostate cancer.
Reliable determination of fPSA has long been the subject to scientific
criticism, due to special analytical difficulties encountered. The
prominent feature of free PSA immunoassays is their suitability for
diagnostic and staging the prostate cancer.
Principle of method
The technology
uses two monoclonal antibodies of high affinity in an immunoradiometric
assay (IRMA) system.
The 125I
labelled signal-antibody binds to an epitope of the fPSA molecule
different from that recognised by the un-labelled capture-antibody. The
two antibodies react simultaneously with the antigen present in
standards or samples which leads to the formation of a capture antibody
- antigen - signal antibody complex, also referred to as a “sandwich”.
During
a 2-hour incubation period with continuous agitation the immuno-complex
is immobilized on the reactive surface of streptavidin coated test
tubes. Reaction mixture is then discarded, test tubes washed
exhaustively, and the radioactivity is measured in a gamma counter.
The
concentration of antigen is directly proportional to the radioactivity
measured in test tubes. By constructing a calibration curve plotting
binding values against a series of calibrators containing known amount
of fPSA, the unknown concentration of fPSA in patient samples can
determined.
Contents of the kit
|
1 bottle |
TRACER, ready to use.
21 ml, containing about 740 kBq 125I-anti-fPSA and
capture anti-PSA antibody in buffer
with red dye and 0.1% NaN3. |
|
6 vials |
STANDARD
1.0 ml per vial, containing 0, 0.1, 0.5, 2, 10, 50 ng/ml fPSA
(WHO ECBS 96/668) in serum with 0.1% Kathon CG. |
|
1 vial |
CONTROL SERUM
1.0 ml human serum with 0.1% Kathon CG.
The concentration of the control serum is specified in
the quality certificate enclosed. |
|
2 boxes |
COATED TUBE, ready to use
2 x 50 reactive test tubes, 12x75 mm, packed in plastic boxes. |
|
1 bottle |
WASH BUFFER CONCENTRATE.
20 ml, containing 0.1% NaN3. See Preparation of
reagents |
|
1 pc |
Quality certificate |
|
1 pc |
Pack leaflet |
Materials, tools and equipment required
Test
tube rack
Precision pipettes with disposable tips (100, 200 and 2000 µl)
Distilled water
Vortex mixer
Shaker
Plastic foil
Adsorbent tissue
Gamma counter
Recommended
tools and equipment
Repeating pipettes (e.g. Eppendorf)
Dispenser with 1-L reservoir (instead of the 2 ml pipette)
Specimen collection and storage
Serum
samples can be prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored at 2-8 °C if the
assay is carried out within 24 hours, otherwise aliquots should be
prepared and stored deep frozen (-20 °C). Frozen samples should be
thawed and thoroughly mixed before assaying. Repeated freezing and
thawing should be avoided. Do not use lipemic, hemolyzed or turbid
specimens.
Preparation of reagents, storage
Add the
wash buffer concentrate (20 ml) to 700 ml distilled water to obtain 720
ml wash solution. Upon dilution store at 2-8 °C until expiry date.
Store
the rest of reagents between 2-8 °C after opening. At this temperature
each reagent is stable until expiry date. The actual expiry date is
given on the package label and in the quality certificate.
CAUTION! Equilibrate all reagents and serum samples to room temperature.
Mix all reagents and samples thoroughly before use. Avoid excessive
foaming.
Assay procedure
(For a quick
guide, refer to Table 1.)
|
1 |
Equilibrate reagents and samples to room temperature
before use. |
|
2 |
Label coated tubes in duplicate for each standard
(S0-S5), control serum and samples. |
|
3 |
Homogenize all reagents and samples by gentle mixing to
avoid foaming. |
|
4 |
Pipette 100 µl of standards, control and samples into
labelled tubes. Use rack to hold the tubes. Do not touch or
scratch the inner bottom of the tubes with pipette tip. |
|
5 |
Pipette 200 µl of tracer into each tube. |
|
6 |
Seal all tubes with a plastic foil. Fix the test tube
rack firmly onto the shaker plate. Turn on the shaker and adjust
an adequate speed such that liquid is constantly rotating or
shaking in each tube. |
|
7 |
Incubate tubes for 2 hours shaking at room temperature.
|
|
8 |
Add 2.0 ml of diluted wash buffer to each tube. Decant
the supernatant from all tubes by the inversion of the rack. In
the upside down position place the rack on an absorbent paper
for 2 minutes. |
|
9 |
Return the tube rack to an upright position, and repeat
Step 8 two more times. |
|
10 |
Count each tube for at least 60 seconds in a gamma
counter. |
|
11 |
Calculate the fPSA concentrations of the samples as
described in Calculation of results or use special
software. |
Table
1. Assay Protocol, Pipetting Guide (all volumes in microliters)
|
Tube |
Total |
Standard |
Sample |
Control |
|
Standard |
|
100 |
|
|
|
Sample |
|
|
100 |
|
|
Control serum |
|
|
|
100 |
|
Tracer |
200 |
200 |
200 |
200 |
|
Shake
for 2 hours at room temperature. |
|
Wash
buffer |
|
2000 |
2000 |
2000 |
|
Decant the fluid and blot on filter paper |
|
Wash
buffer |
|
2000 |
2000 |
2000 |
|
Decant the fluid and blot on filter paper |
|
Wash
buffer |
|
2000 |
2000 |
2000 |
|
Decant the fluid and blot on filter paper |
|
Count
radioactivity (60 sec/tube) |
|
Calculate the results |
Calculation of results
The
calculation is illustrated using representative data. The assay data
collected should be similar to those shown in Table 2.
Calculate the average CPM for each pair of assay tubes. Calculate the
normalized percent binding for each standard, control and sample
respectively by using the following equation:
| |
S1-5 [C, Mx] (cpm) – S0
(cpm) |
|
|
B / T (%) = |
——————————— |
x 100 |
| |
T (cpm) |
|
Using
semi-logarithmic graph paper plot B/T (%) for each standard versus the
corresponding concentration of fPSA.
Determine the fPSA concentration of the unknown samples by interpolation
from the standard curve. Do not extrapolate values beyond the standard
curve range.
Out of
fitting programs applied for computerized data processing logit-log, or
spline fittings can be used. Automated data processing systems are also
available.
Table 2.
Typical assay data
| |
cpm-1
|
cpm-2
|
cpm
mean |
B / T % |
|
Total |
320747 |
323132 |
321940 |
|
|
S0 |
130 |
173 |
152 |
0.05 |
|
S1 |
953 |
1008 |
981 |
0.26 |
|
S2 |
4178 |
4010 |
4094 |
1.22 |
|
S3 |
15849 |
15589 |
15719 |
4.84 |
|
S4 |
70974 |
71314 |
71144 |
22.05 |
|
S5 |
206479 |
209781 |
208130 |
64.60 |
|
C |
16257 |
16807 |
16532 |
5.09 |
Figure 1.
Typical standard curve
(Do not use to calculate sample values)
Characterization of the assay
Typical assay
parameters
Calibration
Free PSA
standards are callibrated against the WHO ECBS 96/668.
Sensitivity
For the
analytical sensitivity 0.02 ng/ml has been obtained by assaying
15 duplicates of the zero standard. The sensitivity has been determined
as the concentration corresponding to the sum of the mean cpm and its
double standard deviation.
For the functional sensitivity, determined as the value
extrapolated to 22% of the inter-assay imprecision profile obtained in
15 independent runs on patient samples with low endogeneous fPSA
concentration, 0.05 ng/ml was obtained.
Hook effect
There
is no high dose “hook effect” up to a fPSA concentration of 1000 ng/ml.
Specificity
The monoclonal
antibodies used in this IRMA kit are specific for fPSA. Less than 0.04%
cross reactivity was found with human kallikreins and human prostate
acid phosphatase.
Precision
4 patient
samples were assayed in 15 replicates to determine intra-assay
precision. Values obtained are shown below.
|
Sample |
Number of replicates |
Mean value |
SD |
CV
% |
|
1 |
15 |
0.17 |
0.01 |
5.5 |
|
2 |
15 |
1.14 |
0.03 |
2.7 |
|
3 |
15 |
4.91 |
0.10 |
2.0 |
|
4 |
15 |
22.7 |
1.75 |
7.7 |
Reproducibility
To determine
inter-assay precision 4 patient samples were measured in duplicates in
15 independent assays by 2 operators using different kit batches. Values
obtained are shown below.
|
Sample |
Number of runs |
Mean value |
SD |
CV
% |
|
1 |
15 |
0.17 |
0.02 |
8.7 |
|
2 |
15 |
1.15 |
0.08 |
6.9 |
|
3 |
15 |
4.18 |
0.15 |
3.6 |
|
4 |
15 |
23.4 |
1.03 |
4.4 |
Expected Values
The optimal
free/total PSA cut-off value is 25%, it was determined by ROC analysis.
It is recommended that each laboratory determine a reference range for
its own patient population.
Procedural notes
1)
Source of error! Reactive test tubes packed in plastic boxes
are not marked individually. Care should be taken not to mix them with
common test tubes. To minimize this risk, never take more tubes than
needed out of plastic box, and put those left after work back to the
box. It is recommended to label assay tubes by a marker pen.
2) Source of error! To ensure efficient rotation, tubes
should be firmed tightly inside the test tube rack. Never use a rack
type with open hole. An uneven or incomplete shaking may result in a
poor assay performance.
3) Addition of wash buffer. For the addition of wash
buffer the use of a common laboratory dispenser equipped with a 1-L
glass bottle, and a flexible outlet tubing end is recommended. In lack
of this tool a large volume syringe attached to a repeating pipette can
be used.
Additional information
Components
from various lots or from kits of different manufacturers should not be
mixed or interchanged.
Precaution
Radioactivity
This product
contains radioactive material. It is the responsibility of the user to
ensure that local regulations or code of practice related to the
handling of radioactive materials are satisfied.
Biohazard
Human blood
products used in the kit have been obtained from healthy human donors.
They were tested individually by using approved methods (EIA, enzyme
immunoassay), and were found to be negative, for the presence of both
Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B
surface Antigen (HBsAg).
Care should
always be taken when handling human specimens to be tested with
diagnostic kits. Even if the subject has been tested, no method can
offer complete assurance that Hepatitis B Virus, Human Immunodeficiency
Virus (HIV-1), or other infectious agents are absent. Human blood
samples should therefore be handled as potentially infectious
materials.
Chemical hazard
Components contain sodium azide as an antimicrobial agent. Dispose of
waste by flushing with copious amount of water to avoid build-up of
explosive metallic azides in copper and lead plumbing. The total azide
present in each pack is 41 mg.
 |
Use by |
 |
In vitro diagnostic medical device |
 |
Control |
 |
Batch code |
 |
Manufacturer |
 |
Standard |
 |
Caution, consult accompanying documents |
 |
Radioactive material |
 |
Coated tube |
 |
Biological risk |
 |
Temperature limitation
Store between 2-8 °C |
 |
Tracer |
 |
Consult instructions for use |
 |
Catalogue number |
 |
Wash buffer |
|